Literature DB >> 2829597

Changes of angiotensin converting enzyme (ACE) levels during activation of the renin-angiotensin-aldosterone system (RAAs).

S Novo1, L Adamo, A Giamporcaro, G Forte, B Longo, V B Gallo, G Licata, A Strano.   

Abstract

The aim of this study was to evaluate the changes of ACE levels during RAAs activation induced by: 1) a continuous graded bicycle ergometer test performed in a group of 15 males health youths aged between 21 and 30 years, with average age of 25.8 +/- 2.85 years; 2) i.m. injection of 20 mg of frusemide in 11 health youths (10 males and 1 female), aged between 20 and 30 years, with average age of 24.09 +/- 2.77 years; 3) dialytic treatment in 25 patients (12 males and 13 females), suffering from chronic renal failure, aged between 26 and 68 years, with average age of 54 +/- 15.42 years. Plasmatic renin activity (PRA), aldosterone (ALD) and ACE levels were determined by RIA in basal conditions and at peak of exercise in group 1, 15 minutes after i.m. injection of frusemide in group 2 and after a session of dialysis in group 3. In all the experimental conditions studied there was an activation of the renin-angiotensin system with significant increase of the PRA, ALD and ACE levels.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2829597     DOI: 10.1007/978-3-0348-9299-5_35

Source DB:  PubMed          Journal:  Agents Actions Suppl        ISSN: 0379-0363


  2 in total

1.  Impaired kidney function and atrial fibrillation in elderly subjects.

Authors:  Rajat Deo; Ronit Katz; Bryan Kestenbaum; Linda Fried; Mark J Sarnak; Bruce M Psaty; David S Siscovick; Michael G Shlipak
Journal:  J Card Fail       Date:  2009-09-03       Impact factor: 5.712

2.  The serum angiotensin-converting enzyme and angiotensin II response to altered posture and acute exercise, and the influence of ACE genotype.

Authors:  David Woods; Julie Sanders; Alun Jones; Emma Hawe; Peter Gohlke; Steve E Humphries; John Payne; Hugh Montgomery
Journal:  Eur J Appl Physiol       Date:  2003-11-01       Impact factor: 3.078

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.